Thorough QT Assessment of Cedazuridine in Healthy Subjects
Status:
Recruiting
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the effect of therapeutic and supratherapeutic oral doses
of cedazuridine on cardiac repolarization, as detected by QTc in healthy subjects, in
accordance with regulatory guidelines. Moxifloxacin will be used to validate the study. Study
duration per participant is approximately 20 days.